{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-168878","form_type":"8-K","ticker":"RNTX","cik":"0001420565","company_name":"Rein Therapeutics, Inc.","filed_at":"2022-06-07T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.618002+00:00","generated_at":"2026-06-25T03:52:40.515253+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"CEO Manuel Aivado appointed principal financial officer after CFO Richard Wanstall resigns","bullets":["CFO Richard J. Wanstall resigned effective May 6, 2022.","On June 5, 2022, CEO Manuel Aivado appointed as principal financial and accounting officer.","Dr. Aivado has served as President and CEO since September 2018; no arrangement or family relationships.","No transactions disclosed between Aivado and company per Item 404(a)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-168878","json":"https://secwatch.observer/filing/0001193125-22-168878.json","markdown":"https://secwatch.observer/filing/0001193125-22-168878.md","text":"https://secwatch.observer/filing/0001193125-22-168878.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420565/000119312522168878/0001193125-22-168878-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420565/000119312522168878/d323390d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T03:52:40.515253+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4f7fe8fb8a","claim":"Richard J. Wanstall resigned as Chief Financial Officer at Rein Therapeutics, Inc..","evidence_excerpt":"Richard J. Wanstall, the Company’s Chief Financial Officer, principal financial officer and principal accounting officer, notified the Company of his resignation, effective May 6, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1420565/000119312522168878/0001193125-22-168878-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"7216c27ecf","claim":"Manuel Aivado was appointed as principal financial officer and principal accounting officer at Rein Therapeutics, Inc..","evidence_excerpt":"On June 5, 2022, the Board of Directors of the Company appointed Manuel Aivado, M.D., Ph.D., the Company’s President and Chief Executive Officer to serve as the Company’s principal financial officer and principal accounting officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1420565/000119312522168878/0001193125-22-168878-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"principal financial officer and principal accounting officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}